A case of bronchial asthma as an immune-related adverse event of pembrolizumab treatment for bladder cancer: A case report

RATIONALE: Bladder cancer is one of the most common cancers worldwide. The anti-programmed cell death protein 1 (PD-1) antibody pembrolizumab, which is an immune checkpoint inhibitor (ICI), has improved survival in bladder cancer. We report a case of bladder cancer that had a high antitumor effect w...

Descripción completa

Detalles Bibliográficos
Autores principales: Hamada, Kazuyuki, Yoshimura, Kiyoshi, Oshinomi, Kazuhiko, Hirasawa, Yuya, Ariizumi, Hirotsugu, Ohkuma, Ryotaro, Shida, Midori, Kubota, Yutaro, Matsui, Hiroto, Ishiguro, Tomoyuki, Sambe, Takehiko, Ishida, Hiroo, Horiike, Atsushi, Wada, Satoshi, Iwamoto, Sanju, Uchida, Naoki, Ogawa, Yoshio, Kobayashi, Shinichi, Tsunoda, Takuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8757941/
https://www.ncbi.nlm.nih.gov/pubmed/35029177
http://dx.doi.org/10.1097/MD.0000000000028339

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8757941/
https://www.ncbi.nlm.nih.gov/pubmed/35029177
http://dx.doi.org/10.1097/MD.0000000000028339

Ejemplares similares